A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2002
11/21/2002	WO2002092600A1 Retinol derivatives potentiation of active substances by micellar preparation
11/21/2002	WO2002092596A1 Novel sulfonate substituted pyrazol pyridine dervivatives
11/21/2002	WO2002092594A1 Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/21/2002	WO2002092573A2 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
11/21/2002	WO2002092129A2 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist
11/21/2002	WO2002092127A1 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
11/21/2002	WO2002092125A1 Compositions for use in treating ige-associated disorders
11/21/2002	WO2002092122A2 Use of osteopontin for the treatment and/or prevention of neurologic diseases
11/21/2002	WO2002092116A1 Targeted delivery of drugs for the treatment of viral infections
11/21/2002	WO2002092107A1 Method and compositions for treating mammalian nerve tissue injuries
11/21/2002	WO2002092102A2 Treatment of conditions relating to hormone deficiencies by administration of progestins
11/21/2002	WO2002092097A1 Composition comprising phosphodiesterase inhibitors for inducing cervical ripening
11/21/2002	WO2002092091A1 Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
11/21/2002	WO2002092083A1 7,8-fused 4$i(h)-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/21/2002	WO2002092073A1 Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
11/21/2002	WO2002092071A1 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
11/21/2002	WO2002092069A1 Permeation enhancers
11/21/2002	WO2002092064A2 Therapeutic method for inducing tolerance
11/21/2002	WO2002092060A1 Abuse-resistant controlled-release opioid dosage form
11/21/2002	WO2002092059A1 Abuse-resistant opioid dosage form
11/21/2002	WO2002092049A2 System for delivering cosmetics and pharmaceuticals
11/21/2002	WO2002092016A2 Therapeutic use of rank antagonists
11/21/2002	WO2002092011A2 Methods of treating antibody-mediated pathologies using agents which inhibit cd21
11/21/2002	WO2002092008A2 Use of il-18 inhibitors for the treatement or prevention of sepsis
11/21/2002	WO2002092003A2 Novel therapeutical quaternary ammonium compositions
11/21/2002	WO2002092000A2 Hbm variants that modulate bone mass and lipid levels
11/21/2002	WO2002091996A2 Methods for treating cancer
11/21/2002	WO2002091992A2 Targeted delivery of drugs for the treatment of parasitic infections
11/21/2002	WO2002091990A2 Prevention of addiction in pain management
11/21/2002	WO2002091969A1 Treating epidermlyosis bullosa with thymosin beta 4
11/21/2002	WO2002091820A1 Nonhuman model animal of oligodendrocyte development disability
11/21/2002	WO2002078716A3 Methylated promoters for intraductal treatment of breast cancer
11/21/2002	WO2002074981A3 Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
11/21/2002	WO2002067870A3 Composition and method for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease
11/21/2002	WO2002066068A3 Method of treating neurological diseases
11/21/2002	WO2002064108A3 Delivery of biologically active agents
11/21/2002	WO2002063308A3 Prediction of wound healing by urinary nitrate assay
11/21/2002	WO2002062343A3 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
11/21/2002	WO2002058792A3 Rehydration composition
11/21/2002	WO2002058733A9 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
11/21/2002	WO2002058532A3 Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof
11/21/2002	WO2002055720A3 Materials and methods relating to protein aggregation in neurodegenerative disease
11/21/2002	WO2002055098A3 Latency associated peptide for providing latency to pharmaceutically active proteins
11/21/2002	WO2002049649A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
11/21/2002	WO2002049629A8 Methods for reducing chronic stress in mammals
11/21/2002	WO2002043785A3 Intraocular implants for preventing transplant rejection in the eye
11/21/2002	WO2002043765A3 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
11/21/2002	WO2002036171A9 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
11/21/2002	WO2002031201A3 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
11/21/2002	WO2002018637A3 Diagnosis and treatment of prostate cancer
11/21/2002	WO2002014467A3 Cng2b: a putative human cyclic nucleotide-gated ion channel
11/21/2002	WO2002011705A3 Composition for combined use of aromatase inhibitors
11/21/2002	WO2002005799A3 Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
11/21/2002	US20020174446 Identification of genes involved in alzheimer's disease using drosophila melanogaster
11/21/2002	US20020173663 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma; benzisoxazole compounds; e.g. ((5,7-dipropyl-3-trifluoromethyl-1,2-benzisoxazol-6-yl)oxy)acetic acid, methyl ester
11/21/2002	US20020173661 Phosphodiesterase-4 (PDE4); thiazole-containing pyridine (N-oxide) compounds; 4-(2-(3,4-Bis(difluoromethoxy)phenyl)-2-(5-(2-(1-hydroxy-1 -methyl)ethyl)thiazolyl)ethyl)pyridine N-oxide for example
11/21/2002	US20020173558 Biocompatibility
11/21/2002	US20020173549 Compositions and methods for treatment of mild cognitive impairment
11/21/2002	US20020173538 Method for sensitizing cancer cells to cancer therapies with a mevalonate-reducing compound
11/21/2002	US20020173514 Pyridine-substituted pyrazolopyridine derivatives
11/21/2002	US20020173513 5HT1a Receptor subtype agonist
11/21/2002	US20020173511 Serotonergic compositions and methods for treatment of mild cognitive impairment
11/21/2002	US20020173510 Nutrient mixture; fatty acid, calcium compound and vitamins
11/21/2002	US20020173505 Antiserotonine agents; respiratory system disorders; antidepressants; eating disorders
11/21/2002	US20020173491 Viricides; drug resistance mixtures
11/21/2002	US20020173475 Methods to inhibit viral replication
11/21/2002	US20020173470 Jasmonate pharmaceutical composition for treatment of cancer
11/21/2002	US20020173461 Methods for enhancing the efficacy of cancer therapy
11/21/2002	US20020173460 Complexing with fibronectins; analyzing, calibration; antiinflammatory agents, respiratory system disorders
11/21/2002	US20020173445 Selective androgen receptor modulators and methods for their identification, design and use
11/21/2002	US20020173022 Polypeptide for use in the diagnosis, prevention and treatment of inflammation and disorders associated with cell proliferation and apoptosis
11/21/2002	US20020172958 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
11/21/2002	US20020172721 Vitamin formulation for cardiovascular health
11/21/2002	US20020172719 Pharmaceutical compositions and methods for managing skin conditions
11/21/2002	US20020172687 Anti-Viral Treatment With Pertussis Toxin B Oligomer
11/21/2002	US20020172682 Using heat shock proteins to increase immune response
11/21/2002	US20020172678 For regulating cellular proliferation and chemotaxis
11/21/2002	US20020172662 Combination therapy (temozolomide and alpha-IFN) for advanced cancer
11/21/2002	US20020172660 For therapy of cancer, viral infections
11/21/2002	CA2778114A1 Abuse-resistant opioid dosage form
11/21/2002	CA2740056A1 Methods and compositions for treating mammalian nerve tissue injuries
11/21/2002	CA2689808A1 Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
11/21/2002	CA2447518A1 Therapeutic use of rank antagonists
11/21/2002	CA2447444A1 Antisense permeation enhancers
11/21/2002	CA2447431A1 Inhibitors of receptor activator of nf-kb and uses thereof
11/21/2002	CA2447395A1 Targeted delivery of drugs for the treatment of parasitic infections
11/21/2002	CA2447139A1 Specific binding proteins and uses thereof
11/21/2002	CA2447052A1 Combined approach to treatment of cancer using a c-myc antisense oligomer
11/21/2002	CA2446991A1 Agents that regulate apoptosis
11/21/2002	CA2446953A1 Methods of treating antibody-mediated pathologies using agents which inhibit cd21
11/21/2002	CA2446859A1 Transgenic animal model of bone mass modulation
11/21/2002	CA2446849A1 Treatment of conditions relating to hormone deficiencies by administration of progestins
11/21/2002	CA2446821A1 Hbm variants that modulate bone mass and lipid levels
11/21/2002	CA2446806A1 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
11/21/2002	CA2446641A1 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
11/21/2002	CA2446589A1 Methods for treating cancer
11/21/2002	CA2446180A1 Cytokine polypeptides
11/21/2002	CA2446108A1 Compositions for use in treating ige-associated disorders
11/21/2002	CA2446106A1 System for delivering cosmetics and pharmaceuticals
11/21/2002	CA2446072A1 Treating epidermolysis bullosa with thymosin beta 4

1 ... 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 ... 1151